BackBionano Genomics- Warrants (21/08/2023) Overview

Bionano Genomics- Warrants (21/08/2023) Current Assets

Bionano Genomics- Warrants (21/08/2023)'s current assets is $39M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$38.98M
13.25% YoYΔ $-5.95M vs prior year quarter

Peer average

Loading

Bionano Genomics- Warrants (21/08/2023) Current Assets History

Loading

Bionano Genomics- Warrants (21/08/2023) vs. peers: Current Assets Comparison

Loading

Bionano Genomics- Warrants (21/08/2023) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bionano Genomics- Warrants (21/08/2023) (BNGOW) FAQ

As of the most recent data (March 2026), BNGOW shows a current assets of $39M. That compares with $45M in the prior-year period — down 13.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BNGOW's current assets is now $39M (was $45M) — a 13.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bionano Genomics- Warrants (21/08/2023) is outperforming or lagging.

Tracking BNGOW's current assets over time shows whether Bionano Genomics- Warrants (21/08/2023) is scaling, shrinking, or reshaping that part of the business. The current reading is $39M That compares with $45M in the prior-year period — down 13.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Bionano Genomics- Warrants (21/08/2023)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $39M) with ownership activity and broader fundamentals.

Bionano Genomics- Warrants (21/08/2023)'s current assets is $39M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.